KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study.

Makoto Uchiyama, Daiji Kambe, Sayaka Hasegawa, Yumiko Imadera, Hironori Yamasaki, Naohisa Uchimura

Sleep 49(3) zsaf291

PMID41001841
PMCIDPMC13017578
DOI10.1093/sleep/zsaf291
发表日期2025-09-26
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:图注未提示 KM 曲线;Figure 1:图注未提示 KM 曲线;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线。
摘要

摘要

STUDY OBJECTIVES: A placebo (PBO)-controlled phase 3 study was conducted to evaluate the efficacy and safety of vornorexant, a novel dual orexin receptor antagonist, in Japanese patients with insomnia. METHODS: Following a 2-week PBO run-in period, 596 patients with insomnia were randomized to receive 5 mg of vornorexant (VOR5), 10 mg of vornorexant (VOR10), or PBO for 2 weeks in a 1:1:1 ratio in double-blind manner, followed by a 1-week PBO run-out period. The primary and key secondary efficacy endpoints were subjective sleep latency and subjective sleep efficiency, respectively, assessed by sleep diary. RESULTS: Subjective sleep latency was significantly improved at week 2 in both groups compared to PBO (differences of the least-squares mean [LSM] changes from baseline in VOR5, -10.6 min [95% CI = -14.2% to -7.0%] p < .001, and VOR10, -10.1 min [-13.8% to -6.5%] p < .001). Subjective sleep efficiency was also significantly improved at 2 weeks in both groups compared to PBO (LSM changes from baseline in VOR5, 3.41% [1.87% to 4.96%] p < .001, and VOR10, 2.94% [1.40% to 4.48%] p < .001). The most common adverse event (AE) was somnolence (VOR5: 3.1%, VOR10: 3.6%, PBO: 1.5%). No AEs of cataplexy, fall, muscular weakness, sleep paralysis, hypnagogic or hypnopompic hallucination, or excessive daytime sleepiness were reported. No withdrawal symptoms or rebound insomnia were observed in the PBO run-out period. CONCLUSIONS: Treatment with 5 and 10 mg of vornorexant significantly improved sleep onset latency and sleep efficiency compared with PBO without relevant safety concerns. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT05453136. Japan Registry of Clinical Trials ID: jRCT2031220209. A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study of TS-142 in Patients with Insomnia Disorder. https://clinicaltrials.gov/study/NCT05453136. https://jrct.mhlw.go.jp/en-latest-detail/jRCT2031220209. Statement of Significance Sleep disturbances lead to physical and mental health issues. Some pharmacotherapies for individuals with insomnia are available, but most of these have concerns including withdrawal, dependence, and next-day residual effects. Therefore, alternative treatment with minimal impact on these issues is highly desirable. This phase 3 study was conducted to confirm the efficacy and safety of vornorexant, a novel dual orexin antagonist having pharmacokinetic characteristics of rapid absorption and elimination, in patients with insomnia. Consequently, both tested doses showed superior efficacy compared to placebo, with significant reductions in subjective sleep latency and increases in sleep efficiency. These findings position vornorexant as a new treatment option for insomnia, offering improvements in sleep while avoiding the concerns associated with traditional hypnotics.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical Abstract无图注
非 KM Figure
Figure 1Study flowchart. * Data of the patients from the site committing GCP violation were not included in all analyses.
非 KM Figure
Figure 2Mean changes from baseline in sleep diary endpoints. (A) sSL (primary endpoint). (B) sSE (key secondary endpoint). (C) sTST (secondary endpoint). (D) sWASO (secondary endpoint). (E) sNAW (secondary endpoint). (F) Urinary frequency (secondary endpoint). Error bars show SEM. Diamond: PBO, circle: VOR5, triangle: VOR10. * p < .05 vs PBO.
非 KM Figure
Figure 3Responder analysis based on sleep diary measurement. The number of patients whose treatment effect was larger than the clinically meaningful threshold. Data are presented as point estimate of the difference from PBO with 95% CIs. a) Patients whose sSL improved from baseline by at least 20 minutes. b) Patients whose sSE improved from baseline by at least 10%. c) Patients whose sTST improved from baseline by at least 30 min.
非 KM Figure